Interstitial Lung Fibrosis Following COVID-19 Pneumonia
- PMID: 36010377
- PMCID: PMC9407299
- DOI: 10.3390/diagnostics12082028
Interstitial Lung Fibrosis Following COVID-19 Pneumonia
Abstract
Background and Objectives: Pulmonary fibrosis represents a stage of normal physiologic response to inflammatory aggression, mostly self-limiting and reversible; however, numerous patients treated for SARS-CoV-2 pneumonia present after release from hospital residual lung fibrosis. In this article, we aim to present an optimization method for evaluating pulmonary fibrosis by quantitative analysis, to identify the risk factors/predictors for pulmonary fibrosis in patients with SARS-CoV-2 infection, and to characterize the impact of pulmonary fibrosis on the symptomatology of patients after release from the hospital. Materials and Methods: We performed a prospective observational study on 100 patients with severe forms of pneumonia, with a control group of 61 non-COVID normal patients. Results: We found persistent interstitial changes consistent with fibrotic changes in 69% of patients. The risk of fibrosis was proportional to the values of erythrocyte sedimentation rate (ESR), C reactive protein (CRP), and lactate dehydrogenase (LDH), and to the duration of hospitalization. The imaging parameters correlated with increased risk for interstitial fibrosis were the number of affected pulmonary lobes and the percent of interstitial pulmonary fibrosis. Conclusions: The main risk factors for pulmonary fibrosis post-COVID-19 identified in our study are increased ESR, CRP, LDH, duration of hospitalization and the severity of pneumonia.
Keywords: SARS-COV-2; fibrosis predictors; long COVID; pulmonary fibrosis; quantitative analysis; risk factors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Surviving COVID-19 and Battling Fibrosis: A Retrospective Cohort Study Across Three Pandemic Waves.Diagnostics (Basel). 2024 Dec 13;14(24):2811. doi: 10.3390/diagnostics14242811. Diagnostics (Basel). 2024. PMID: 39767173 Free PMC article.
-
Pulmonary Involvement in SARS-CoV-2 Infection Estimates Myocardial Injury Risk.Medicina (Kaunas). 2022 Oct 11;58(10):1436. doi: 10.3390/medicina58101436. Medicina (Kaunas). 2022. PMID: 36295594 Free PMC article.
-
Interstitial lung abnormalities after hospitalization for COVID-19 in patients with cancer: A prospective cohort study.Cancer Med. 2023 Sep;12(17):17753-17765. doi: 10.1002/cam4.6396. Epub 2023 Aug 18. Cancer Med. 2023. PMID: 37592894 Free PMC article.
-
[Clinical, radiological, and histopathological features of pulmonary post-COVID syndrome : A form of autoimmune-mediated interstitial lung disease?].Pathologe. 2021 Dec;42(Suppl 2):160-164. doi: 10.1007/s00292-021-01024-6. Epub 2021 Nov 30. Pathologe. 2021. PMID: 34850268 Free PMC article. Review. German.
-
Human-Based Advanced in vitro Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19.Front Med (Lausanne). 2021 May 7;8:644678. doi: 10.3389/fmed.2021.644678. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34026781 Free PMC article. Review.
Cited by
-
Persisting Shadows: Unraveling the Impact of Long COVID-19 on Respiratory, Cardiovascular, and Nervous Systems.Infect Dis Rep. 2023 Dec 15;15(6):806-830. doi: 10.3390/idr15060072. Infect Dis Rep. 2023. PMID: 38131885 Free PMC article. Review.
-
Comparative Evaluation of the Clinical Severity of COVID-19 of Vaccinated and Unvaccinated Patients in Southeastern Romania in the First 6 Months of 2022, during the Omicron Wave.Healthcare (Basel). 2023 Aug 1;11(15):2184. doi: 10.3390/healthcare11152184. Healthcare (Basel). 2023. PMID: 37570424 Free PMC article.
-
Chronic Pulmonary Manifestations of COVID-19 Infection: Imaging Evaluation.Radiology. 2023 Apr;307(2):e222379. doi: 10.1148/radiol.222379. Epub 2023 Jan 24. Radiology. 2023. PMID: 36692398 Free PMC article. Review.
-
The Role of Cytokines and Molecular Pathways in Lung Fibrosis Following SARS-CoV-2 Infection: A Physiopathologic (Re)view.Biomedicines. 2024 Mar 13;12(3):639. doi: 10.3390/biomedicines12030639. Biomedicines. 2024. PMID: 38540252 Free PMC article. Review.
-
Surviving COVID-19 and Battling Fibrosis: A Retrospective Cohort Study Across Three Pandemic Waves.Diagnostics (Basel). 2024 Dec 13;14(24):2811. doi: 10.3390/diagnostics14242811. Diagnostics (Basel). 2024. PMID: 39767173 Free PMC article.
References
-
- Wang H., Paulson K.R., Pease S.A., Watson S., Comfort H., Zheng P., Aravkin A.Y., Bisignano C., Barber R.M., Alam T., et al. Estimating excess mortality due to the COVID-19 pandemic: A systematic analysis of COVID-19-related mortality, 2020–2021. Lancet. 2022;399:1513–1536. doi: 10.1016/S0140-6736(21)02796-3. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous